Pediatric Mastocytosis Review Distinguishes Clonal Disease From MCAS
Pediatric mastocytosis differs from adult disease in its presentation, molecular profile, evaluation, and prognosis, according to a clinical management review published in The Journal of Allergy and Clinical Immunology: In Practice. The authors also distinguish clonal mastocytosis from MCAS while describing the mast cell activation symptoms that may accompany pediatric mastocytosis.
Mastocytosis and MCAS Differ
Mastocytosis is characterized by clonal expansion and infiltration of mast cells in the skin or other tissues and organs. By contrast, the review reports that children with MCAS are usually diagnosed with secondary MCAS associated with an IgE-mediated allergic etiology.
The distinction is clinically relevant because mast cell activation can occur within mastocytosis without making mastocytosis and MCAS interchangeable diagnoses. Children with mastocytosis may develop mediator-related manifestations, including swelling of skin lesions, pruritus, flushing, blistering, gastrointestinal cramping, diarrhea, headache, and fatigue.
Pediatric mastocytosis usually begins at birth or within the first 2 years of life. Most affected children have cutaneous mastocytosis, whereas systemic mastocytosis—which predominates among adults—is rare in children.
Cutaneous disease may present as maculopapular cutaneous mastocytosis, generally the polymorphic variant; cutaneous mastocytoma; or diffuse cutaneous mastocytosis. Monomorphic maculopapular lesions may indicate disease that persists into adulthood and is often associated with systemic mastocytosis.
Diagnostic and Molecular Findings
Children with cutaneous mastocytosis may carry mutations in different regions of the KIT gene. KIT D816V predominates among children with systemic disease.
Evaluation is mainly noninvasive and includes skin inspection, assessment for Darier sign, serum tryptase measurement, and blood testing for a KIT variant. Darier sign consists of reddening and urticarial swelling after mechanical irritation of a lesion due to mast cell mediator release.
The review notes that bone marrow biopsy is reserved for children with clinical suspicion of systemic mastocytosis. In adults, diagnosis of systemic mastocytosis is based on bone marrow examination to assess major and minor diagnostic criteria.
Clinical Implications
Pediatric mastocytosis generally has a favorable prognosis, with spontaneous resolution of cutaneous lesions and mediator-related symptoms after several years or around puberty. Anaphylaxis is also less frequent among children than adults.
Management focuses on avoiding mast cell activation triggers and controlling mediator-related symptoms. Options include H1 and H2 antihistamines, cromolyn, and omalizumab.
For systemic mastocytosis, a tyrosine kinase inhibitor tailored to the identified KIT variant may be considered. The source does not provide comparative efficacy or safety data for these therapies.
Reference
Carter MC, Lange M, Alvarez-Twose I, et al. Management of mastocytosis and mast cell activation in children. J Allergy Clin Immunol Pract. 2026;14(1):30-42. doi:10.1016/j.jaip.2025.11.016
Key Clinical Summary
- Pediatric mastocytosis is a rare clonal mast cell disorder that usually begins before age 2 years, remains skin-limited, and may resolve spontaneously around puberty.
- Mast cell activation symptoms can occur with mastocytosis but are not presented as synonymous with mast cell activation syndrome (MCAS).
- Children diagnosed with MCAS most commonly have secondary MCAS related to an immunoglobulin E (IgE)–mediated allergic cause.https://www.jaci-inpractice.org/article/S2213-2198(25)01115-8/abstract
